KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Pacific Biosciences Of California (PACB) over the last 13 years, with Q3 2025 value amounting to $29.2 million.

  • Pacific Biosciences Of California's Accumulated Expenses rose 5207.21% to $29.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.2 million, marking a year-over-year increase of 5207.21%. This contributed to the annual value of $22.6 million for FY2024, which is 5056.66% down from last year.
  • Latest data reveals that Pacific Biosciences Of California reported Accumulated Expenses of $29.2 million as of Q3 2025, which was up 5207.21% from $26.5 million recorded in Q2 2025.
  • Pacific Biosciences Of California's Accumulated Expenses' 5-year high stood at $45.7 million during Q4 2023, with a 5-year trough of $14.7 million in Q1 2021.
  • Its 5-year average for Accumulated Expenses is $26.6 million, with a median of $25.2 million in 2022.
  • Per our database at Business Quant, Pacific Biosciences Of California's Accumulated Expenses skyrocketed by 10899.71% in 2021 and then crashed by 5056.66% in 2024.
  • Over the past 5 years, Pacific Biosciences Of California's Accumulated Expenses (Quarter) stood at $36.3 million in 2021, then decreased by 10.11% to $32.6 million in 2022, then skyrocketed by 40.23% to $45.7 million in 2023, then plummeted by 50.57% to $22.6 million in 2024, then rose by 29.11% to $29.2 million in 2025.
  • Its Accumulated Expenses stands at $29.2 million for Q3 2025, versus $26.5 million for Q2 2025 and $29.3 million for Q1 2025.